Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)
Sponsor: Bayer
Listed as NCT04319783, this PHASE2 trial focuses on Advanced Prostate Carcinoma and Cancer of Prostate and remains ongoing. Sponsored by Bayer, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Dec 2022 — Mar 2024 [monthly]
Recruiting PHASE2
-
Oct 2021 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Peter MacCallum Cancer Centre, Australia
- Trans Tasman Radiation Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .